Antibody-Conjugated Nanogel with Two Immune Checkpoint Inhibitors for Enhanced Cancer Immunotherapy

Area of Science:

• Biotechnology
• Immunology
• Materials Science

Background:

• Cancer immunotherapy using immune checkpoint inhibitors (ICIs) stimulates antitumor responses but faces challenges with high cost and limited efficacy.
• Existing treatments struggle to effectively target and eliminate solid tumors.

Purpose of the Study:

• To develop and evaluate an antibody-conjugated nanogel (ANGel) system to potentiate the efficacy of immune checkpoint inhibitor monoclonal antibodies (mAbs).
• To investigate the therapeutic potential of ANGel in preclinical models of breast cancer.

Main Methods:

• An antibody-conjugated nanogel (ANGel) was synthesized using N-isopropylacrylamide-co-acrylic acid and protein A.
• The ANGel was surface-conjugated with cytotoxic-T-lymphocyte-associated antigen 4 and programmed death ligand-1 mAbs.
• The efficacy of the bispecific ANGel was assessed in vitro against breast cancer cell lines (MCF-7, MDA-MB-231) and in vivo in a 4T1-luciferase-2 orthotopic syngeneic tumor model.

Main Results:

• Bispecific ANGel treatment significantly reduced breast cancer cell survival in vitro compared to mAb treatment alone.
• In vivo, ANGel demonstrated a significant decrease in tumor burden and prolonged survival in animals with triple-negative breast cancer.
• ANGel showed sustained anticancer effects at the tumor site and adaptability in linking multiple antibodies.

Conclusions:

• Antibody-conjugated nanogel (ANGel) potentiates the efficacy of immune checkpoint inhibitors for cancer immunotherapy.
• ANGel offers a new paradigm for treating solid tumors by enhancing drug delivery and sustained therapeutic effect.
• This approach presents a versatile platform for developing more effective cancer immunotherapies.